Subtype
Soft Tissue Sarcoma
CI-CAN-00001533Explore in graph →
338 active trials9 approved drugs37 evidence items
- NCIt
- C9306
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001533Explore in graph →
Clinical trials
1,383 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (195)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06593899 | The Total Neoadjuvant Therapy for Soft Tissue Sarcoma of the Extremities | unknown | Phase 2 | 51 | Fujian Medical University Union HospitalOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05955105 | A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies | unknown | Phase 1 / Phase 2 | 200 | Innolake BiopharmINDUSTRY | 1 | May 21, 2024 | clinicaltrials |
| NCT04480502 |
| ENVASARC: Envafolimab And Envafolimab With Ipilimumab In Patients With Undifferentiated Pleomorphic Sarcoma Or Myxofibrosarcoma(ENVASARC) |
| unknown |
| Phase 2 |
| 207 |
| Tracon Pharmaceuticals Inc.INDUSTRY |
| 2 |
| May 17, 2024 |
| clinicaltrials |
| NCT03993106 | A Study of sEphB4-HSA in Kaposi Sarcoma | unknown | Phase 2 | 65 | Vasgene Therapeutics, IncINDUSTRY | 1 | May 2, 2024 | clinicaltrials |
| NCT05189483 | Albumin-bound Paclitaxel Plus Camrelizumab for Advanced Soft Tissue Sarcoma. | unknown | Phase 2 | 40 | Henan Cancer HospitalOTHER_GOV | 1 | Feb 7, 2024 | clinicaltrials |
| NCT03242382 | Trial of Palbociclib in Second Line of Advanced Sarcomas With CDK4 Overexpression.(PalboSarc) | unknown | Phase 2 | 40 | Grupo Espanol de Investigacion en SarcomasOTHER | 1 | Jan 23, 2024 | clinicaltrials |
| NCT04589754 | Adriamycin and Ifosfamide Combined With Sintilimab | unknown | Phase 2 | 176 | Sun Yat-sen UniversityOTHER | 1 | Jan 2, 2024 | clinicaltrials |
| NCT05329792 | L19IL2/L19TNF in Skin Cancer Patients(IntriNSiC) | unknown | Phase 2 | 70 | Philogen S.p.A.INDUSTRY | 3 | Oct 6, 2023 | clinicaltrials |
| NCT05448820 | YH001 Plus Envafolimab With or Without Doxorubicin in Patients With Advanced or Metastatic Sarcoma | unknown | Phase 1 / Phase 2 | 15 | Tracon Pharmaceuticals Inc.INDUSTRY | 1 | Sep 21, 2023 | clinicaltrials |
| NCT05266196 | A Rollover Protocol to Allow for Continued Access to the LSD1 Inhibitor Seclidemstat (SP-2577) | unknown | Phase 1 / Phase 2 | 10 | Salarius Pharmaceuticals, LLCINDUSTRY | 1 | Aug 1, 2023 | clinicaltrials |
| NCT04138381 | Selinexor as Single Agent and With Imatinib in Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (SeliGIST)(SeliGIST) | unknown | Phase 1 / Phase 2 | 30 | Grupo Espanol de Investigacion en SarcomasOTHER | 1 | Mar 27, 2023 | clinicaltrials |
| NCT05131386 | Multicohort Trial of Trabectedin and Low-dose Radiation Therapy in Advanced/Metastatic Sarcomas(SYNERGIAS) | unknown | Phase 2 | 85 | Grupo Espanol de Investigacion en SarcomasOTHER | 1 | Mar 27, 2023 | clinicaltrials |
| NCT03475953 | A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors(REGOMUNE) | unknown | Phase 1 / Phase 2 | 747 | Institut BergoniéOTHER | 1 | Mar 3, 2023 | clinicaltrials |
| NCT05656144 | Cadonilimab in the Treatment of Advanced Soft Tissue Sarcoma | unknown | Phase 2 | 49 | Peking University Cancer Hospital & InstituteOTHER | 0 | Dec 19, 2022 | clinicaltrials |
| NCT05602415 | Anlotinib and Radiotherapy in Resectable Soft Tissue Sarcoma | unknown | Phase 2 | 41 | Ruijin HospitalOTHER | 1 | Nov 2, 2022 | clinicaltrials |
| NCT04012827 | Apatinib Mesylate Combined With Doxorubicin and Ifosfamide in Advanced Soft-tissue Sarcoma | unknown | Phase 2 | 108 | Sun Yat-sen UniversityOTHER | 1 | Sep 7, 2022 | clinicaltrials |
| NCT05518526 | Phase 1b/2 Study of Liposomal Annamycin (L-Annamycin) in Subjects With Previously Treated Soft-Tissue Sarcomas (STS) With Pulmonary Metastases(ANNA-SARC) | unknown | Phase 1 / Phase 2 | 64 | Maria Sklodowska-Curie National Research Institute of OncologyOTHER | 1 | Aug 26, 2022 | clinicaltrials |
| NCT04065152 | Phase II Multicenter Study of Talimogene Laherparepvec in Classic or Endemic Kaposi Sarcoma(KAPVEC) | unknown | Phase 2 | 20 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Jun 10, 2022 | clinicaltrials |
| NCT05142631 | Fruquintinib in the Treatment of Soft Tissue Sarcoma | unknown | Phase 2 | 31 | Fudan UniversityOTHER | 1 | Mar 2, 2022 | clinicaltrials |
| NCT02630368 | A Study of Metronomic CP and JX-594 in Patients With Advanced Breast Cancer and Advanced Soft-tissue Sarcoma (METROmaJX)(METROmaJX) | unknown | Phase 1 / Phase 2 | 197 | Institut BergoniéOTHER | 1 | Feb 2, 2022 | clinicaltrials |
| NCT05193214 | A Phase II Study for 609A in the Treatment of Advanced Undifferentiated Pleomorphic Sarcoma | unknown | Phase 2 | 30 | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.INDUSTRY | 1 | Jan 14, 2022 | clinicaltrials |
| NCT05138146 | A Phase 2 Clinical Study of Evaluation of Recombinant Anti-PD-1 Humanized Monoclonal Antibody Injection (609A) Combined With Doxorubicin Hydrochloride in the Treatment of Metastatic/Unresectable Non-specific Soft Tissue Sarcoma | unknown | Phase 2 | 70 | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.INDUSTRY | 1 | Nov 30, 2021 | clinicaltrials |
| NCT04910126 | Camrelizumab Plus Doxorubicin for the First Line Treatment of Adcanced Soft Tissue Sarcoma | unknown | Phase 2 | 84 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jun 2, 2021 | clinicaltrials |
| NCT03623581 | Clinical Trial in Chinese Patients of Elapsed/Metastatic/Unresectable Alveolar Soft Part Sarcoma(GB226) | unknown | Phase 2 | 35 | Genor Biopharma Co., Ltd.INDUSTRY | 1 | Mar 3, 2021 | clinicaltrials |
| NCT04765228 | Pegylated Liposomal Doxorubicin Combined With Anlotinib for Neoadjuvant Treatment of Soft Tissue Sarcoma | unknown | Phase 2 | 45 | Yong ChenOTHER | 1 | Feb 21, 2021 | clinicaltrials |
| NCT03989596 | Hypofractionated Radiotherapy With Hyperthermia in Unresectable or Marginally Resectable Soft Tissue Sarcomas(SINDIR) | unknown | Phase 2 | 30 | Maria Sklodowska-Curie National Research Institute of OncologyOTHER | 1 | Feb 1, 2021 | clinicaltrials |
| NCT03651375 | Hypofractionated Radiotherapy With Sequential Chemotherapy in Marginally Resectable Soft Tissue Sarcomas of Extremities or Trunk Wall(UN-RESARC) | unknown | Phase 2 | 46 | Maria Sklodowska-Curie National Research Institute of OncologyOTHER | 1 | Jan 22, 2021 | clinicaltrials |
| NCT04606108 | Study of Camrelizumab in Combination With Neoadjuvant Chemotherapy in the Treatment of High-risk Soft Tissue Sarcoma | unknown | Phase 2 | 62 | Sun Yat-sen UniversityOTHER | 1 | Oct 28, 2020 | clinicaltrials |
| NCT04356872 | The Combination of Sintilimab and AI (Doxorubicin, ADM/Ifosfamide, IFO) for the First Line Treatment of Select Type of Metastatic/Unresectable Soft Tissue Sarcoma | unknown | Phase 2 | 45 | Fudan UniversityOTHER | 1 | Jul 14, 2020 | clinicaltrials |
| NCT02968303 | Induction Therapy With Vemurafenib and Cobimetinib to Optimize Nivolumab and Ipilimumab Therapy(COWBOY) | unknown | Phase 2 | 200 | Radboud University Medical CenterOTHER | 1 | Jun 5, 2020 | clinicaltrials |
| NCT03268772 | PLD and IFO As First-line Treatment for Patients With Advanced or Metastatic STS | unknown | Phase 2 | 40 | Fudan UniversityOTHER | 1 | Apr 22, 2020 | clinicaltrials |
| NCT03168061 | Dose-Escalation and Expansion Trial of NC-6300 in Patients With Advanced Solid Tumors or Soft Tissue Sarcoma | unknown | Phase 1 / Phase 2 | 150 | NanoCarrier Co., Ltd.INDUSTRY | 1 | Feb 28, 2020 | clinicaltrials |
| NCT04239443 | Clinical Study of PD-1 Monoclonal Antibody SHR-1210 and Apatinib in Advanced NSCLC, Soft Tissue Sarcoma, and Uterine Cancer | unknown | Phase 2 | 120 | Hunan Cancer HospitalOTHER | 1 | Jan 27, 2020 | clinicaltrials |
| NCT03139487 | A Randomized Phase II Open Label Study to Compare the Safety and Efficacy of Subcutaneous Dalteparin Versus Direct Oral Anticoagulants for Cancer-associated Venous Thromboembolism(PRIORITY) | unknown | Phase 2 | 176 | Asan Medical CenterOTHER | 1 | Jan 6, 2020 | clinicaltrials |
| NCT03638206 | Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies | unknown | Phase 1 / Phase 2 | 73 | Shenzhen BinDeBio Ltd.INDUSTRY | 1 | Dec 11, 2019 | clinicaltrials |
| NCT03469804 | Phase II Multicentric Study of Pembrolizumab in Classic or Endemic Kaposi's Sarcoma(KAPKEY) | unknown | Phase 2 | 17 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Oct 21, 2019 | clinicaltrials |
| NCT04126811 | Apatinib Combined With Chemotherapy in the Treatment of Soft Tissue Sarcoma | unknown | Phase 2 | 120 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Oct 15, 2019 | clinicaltrials |
| NCT03946943 | Study of Anlotinib Hydrochloride and Toripalimab in Subjects With Unresectable or Metastatic Undifferentiated Pleomorphic Sarcoma | unknown | Phase 2 | 25 | Di WuOTHER | 1 | Jul 10, 2019 | clinicaltrials |
| NCT03815474 | Anlotinib Hydrochloride Combined With Epirubicin and Ifosfamide for Soft Tissue Sarcoma Patients(ALTER-S005) | unknown | Phase 2 | 47 | Liaoning Cancer Hospital & InstituteOTHER | 1 | Jul 9, 2019 | clinicaltrials |
| NCT01337401 | A Trial of Cediranib in the Treatment of Patients With Alveolar Soft Part Sarcoma (CASPS)(CASPS) | unknown | Phase 2 | 36 | Institute of Cancer Research, United KingdomOTHER | 3 | Jan 24, 2019 | clinicaltrials |
| NCT03792542 | Anlotinib Hydrochloride For Advanced Soft Tissue Sarcoma Patients Who Do Not Receive Chemotherapy | unknown | Phase 2 | 44 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Jan 3, 2019 | clinicaltrials |
| NCT03219671 | Nivolumab and Ipilimumab in Classical Kaposi Sarcoma (CKS) | unknown | Phase 2 | 20 | Alona ZerOTHER | 1 | Dec 26, 2018 | clinicaltrials |
| NCT02942537 | Study of Volume Reduction of Uterine Fibroids After Embolization or Microwave Treatment(MYOMIC1) | unknown | Phase 2 / Phase 3 | 36 | Karolinska InstitutetOTHER | 1 | Oct 2, 2018 | clinicaltrials |
| NCT01807468 | Haploidentical Stem Cell Transplantation and NK Cell Therapy in Patients With High-risk Solid Tumors | unknown | Phase 2 | 12 | Samsung Medical CenterOTHER | 1 | Sep 18, 2018 | clinicaltrials |
| NCT02784015 | Response Based Treatment for Children With Unresectable Localized Soft Tissue Sarcoma | unknown | Phase 2 | 41 | Samsung Medical CenterOTHER | 1 | Sep 18, 2018 | clinicaltrials |
| NCT03550703 | Open Label Immunotherapy of Myoma(V3-myoma) | unknown | Phase 2 | 30 | Immunitor LLCINDUSTRY | 1 | Jul 6, 2018 | clinicaltrials |
| NCT03509168 | The Efficacy and Safety of Preoperative Misoprostol in Blood-loss Reduction During Myomectomy.(MM) | unknown | Phase 2 / Phase 3 | 46 | Makerere UniversityOTHER | 1 | Apr 30, 2018 | clinicaltrials |
| NCT02982486 | A Phase II of Nivolumab Plus Ipilimumab in Non-resectable Sarcoma and Endometrial Carcinoma | unknown | Phase 2 | 60 | Assaf-Harofeh Medical CenterOTHER_GOV | 0 | Nov 1, 2017 | clinicaltrials |
| NCT03096912 | A Study Assessing Efficacy & Safety of Ribociclib in Patients With Advanced Well/Dedifferentiated Liposarcoma | unknown | Phase 2 | 30 | Assaf-Harofeh Medical CenterOTHER_GOV | 1 | Oct 25, 2017 | clinicaltrials |
| NCT03171389 | POETIG Trial - POnatinib After rEsisTance to Imatinib in GIST(POETIG) | unknown | Phase 2 | 81 | Sebastian BauerOTHER | 1 | May 31, 2017 | clinicaltrials |
Data updated 22 days agoSource updated Sep 19, 2024source: clinicaltrials